Follow The Filings

RCUS position history

The shares of Arcus Biosciences (RCUS) that DAFNA Capital Management LLC reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2021 Q3: 123,700 shares, $4.3M, 1.1% of portfolio
  2. 2021 Q4: 117,200 shares, $4.7M, 1.2% of portfolio, Reduce −5.3%
  3. 2022 Q1: 145,217 shares, $4.6M, 1.2% of portfolio, Add +23.9%
  4. 2022 Q2: 187,717 shares, $4.8M, 1.3% of portfolio, Add +29.3%
  5. 2022 Q3: 178,717 shares, $4.7M, 1.3% of portfolio, Reduce −4.8%
  6. 2022 Q4: 142,217 shares, $2.9M, 0.83% of portfolio, Reduce −20.4%
  7. 2023 Q1: 175,217 shares, $3.2M, 0.96% of portfolio, Add +23.2%
  8. 2023 Q2: 225,717 shares, $4.6M, 1.3% of portfolio, Add +28.8%
  9. 2023 Q3: 222,717 shares, $4M, 1.2% of portfolio, Reduce −1.3%
  10. 2023 Q4: 232,717 shares, $4.4M, 1.1% of portfolio, Add +4.5%
  11. 2024 Q1: 231,717 shares, $4.4M, 1.00% of portfolio, Reduce −0.4%
  12. 2024 Q2: 253,217 shares, $3.9M, 0.92% of portfolio, Add +9.3%
  13. 2024 Q3: 256,717 shares, $3.9M, 0.93% of portfolio, Add +1.4%
  14. 2024 Q4: 254,217 shares, $3.8M, 0.96% of portfolio, Reduce −1.0%
  15. 2025 Q1: 625,126 shares, $4.9M, 1.4% of portfolio, Add +145.9%
  16. 2025 Q2: 627,626 shares, $5.1M, 1.4% of portfolio, Add +0.4%
  17. 2025 Q3: 627,626 shares, $8.5M, 2.1% of portfolio
  18. 2025 Q4: 431,329 shares, $10M, 2.4% of portfolio, Reduce −31.3%
  19. 2026 Q1: 443,829 shares, $9.6M, 2.2% of portfolio, Add +2.9%
  20. 2026 Q2: 441,829 shares, $14M, 2.6% of portfolio, Reduce −0.5%
Holdings date Value % of holdings Shares Filing date All 13F holders